EP Patent

EP1457206A1 — Combined use of a fibrate and orlistat for the treatment of obesity

Assigned to Fournier Laboratories Ireland Ltd · Expires 2004-09-15 · 22y expired

What this patent protects

The present invention relates to the use of a fibrate and orlistat to treat patients suffering from obesity.

USPTO Abstract

The present invention relates to the use of a fibrate and orlistat to treat patients suffering from obesity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1457206A1
Jurisdiction
EP
Classification
—
Expires
2004-09-15
Drug substance claim
No
Drug product claim
No
Assignee
Fournier Laboratories Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.